This page brings together the Agency's latest information on cancer. It lists:
This is a summary of the European public assessment report (EPAR) for Glivec. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in...
Sprycel is a cancer medicine. It is used to treat adults with the following types of leukaemia (cancer of the white blood cells): chronic myeloid leukaemia (CML) in the ‘chronic’ phase in newly...
This is a summary of the European public assessment report (EPAR) for Neofordex. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use...
This is a summary of the European public assessment report (EPAR) for Fulvestrant Mylan. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions...
Zoledronic Acid Accord is a medicine used to prevent bone complications in adults with advanced cancer that is affecting the bone. This includes fractures (breaks in the bone), spinal compression (...
Preliminary results from the ANNOUNCE study show that Lartruvo (olaratumab) in combination with doxorubicin is not more effective at prolonging the lives of patients with soft tissue cancer than doxorubicin alone.
Development of Kymriah and Yescarta supported through PRIME The European Medicines Agency (EMA) has recommended the first two marketing authorisations for chimeric antigen receptors (CAR) T-cells medicines in the European Union (EU). Kymriah (...
Nine medicines recommended for approval, including the first two CAR-T cell therapies in the EU The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended nine medicines for approval, including six orphan...
Preliminary assessment show no increase in frequency of known side effect The European Medicines Agency (EMA) is investigating the cancer medicine docetaxel following cases of neutropenic enterocolitis in patients in France, most of whom were being...
Review of liver cancer risk not conclusive and further studies are needed EMA's Pharmacovigilance Risk Assessment Committee (PRAC) has confirmed that patients treated with medicines known as direct-acting antivirals for hepatitis C may be at risk of...
Watch live broadcast of expert discussion at EMA A workshop on the scientific and regulatory challenges of innovative cancer immunotherapy medicines based on genetically modified T-cells (white blood cells that normally fight off viruses and...
The innovation and biomarkers in cancer drug development (IBCD) 2018 event will embrace the full...
The third multi-stakeholder Paediatric Strategy Forum, jointly organised by EMA and ACCELERATE will...
The objective of this workshop is to facilitate the long-term follow up of CAR-T cell products in a...
Biological drivers that define cancer course across anatomical sites and histologies offer an...